AMICAS has agreed to terminate its previously announced agreement with Thoma Bravo and instead has entered into a merger agreement with Merge Healthcare, the company announced this morning. Merge will acquire all outstanding shares of AMICAS in an all-cash deal valued at $6.05 per share, a 35% premium to Thoma Bravo’s offer and a 39% premium to the average monthly share price.
"We are very pleased with this significant positive step toward successfully combining these two great companies," said Justin Dearborn, Merge CEO. "Merge and AMICAS have strong histories of innovation in medical imaging software, experienced employees and engaged customers. As a combined company, our suite of health IT solutions will encompass a broad range of medical and biopharmaceutical imaging solutions to meet the needs of today’s medical imaging providers. In addition, Merge’s OEM and CAD technologies, international and eCommerce distribution channels, and additional market segments such as clinical trials provide new opportunities for AMICAS products and customers. On behalf of everyone at Merge, I look forward to welcoming and working closely with the AMICAS team."